157 related articles for article (PubMed ID: 18172270)
1. Clinical and molecular responses in lung cancer patients receiving Romidepsin.
Schrump DS; Fischette MR; Nguyen DM; Zhao M; Li X; Kunst TF; Hancox A; Hong JA; Chen GA; Kruchin E; Wright JJ; Rosing DR; Sparreboom A; Figg WD; Steinberg SM
Clin Cancer Res; 2008 Jan; 14(1):188-98. PubMed ID: 18172270
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of the antitumor efficacy, pharmacokinetics, and pharmacodynamics of the histone deacetylase inhibitor depsipeptide in childhood cancer models in vivo.
Graham C; Tucker C; Creech J; Favours E; Billups CA; Liu T; Fouladi M; Freeman BB; Stewart CF; Houghton PJ
Clin Cancer Res; 2006 Jan; 12(1):223-34. PubMed ID: 16397046
[TBL] [Abstract][Full Text] [Related]
3. Romidepsin (depsipeptide) induced cell cycle arrest, apoptosis and histone hyperacetylation in lung carcinoma cells (A549) are associated with increase in p21 and hypophosphorylated retinoblastoma proteins expression.
Vinodhkumar R; Song YS; Devaki T
Biomed Pharmacother; 2008 Feb; 62(2):85-93. PubMed ID: 17644301
[TBL] [Abstract][Full Text] [Related]
4. Histone deacetylase inhibitor panobinostat induces clinical responses with associated alterations in gene expression profiles in cutaneous T-cell lymphoma.
Ellis L; Pan Y; Smyth GK; George DJ; McCormack C; Williams-Truax R; Mita M; Beck J; Burris H; Ryan G; Atadja P; Butterfoss D; Dugan M; Culver K; Johnstone RW; Prince HM
Clin Cancer Res; 2008 Jul; 14(14):4500-10. PubMed ID: 18628465
[TBL] [Abstract][Full Text] [Related]
5. Phase I study of depsipeptide in pediatric patients with refractory solid tumors: a Children's Oncology Group report.
; Fouladi M; Furman WL; Chin T; Freeman BB; Dudkin L; Stewart CF; Krailo MD; Speights R; Ingle AM; Houghton PJ; Wright J; Adamson PC; Blaney SM
J Clin Oncol; 2006 Aug; 24(22):3678-85. PubMed ID: 16877737
[TBL] [Abstract][Full Text] [Related]
6. Histone deacetylase inhibitor FK228 activates tumor suppressor Prdx1 with apoptosis induction in esophageal cancer cells.
Hoshino I; Matsubara H; Hanari N; Mori M; Nishimori T; Yoneyama Y; Akutsu Y; Sakata H; Matsushita K; Seki N; Ochiai T
Clin Cancer Res; 2005 Nov; 11(21):7945-52. PubMed ID: 16278420
[TBL] [Abstract][Full Text] [Related]
7. Phase I study of decitabine-mediated gene expression in patients with cancers involving the lungs, esophagus, or pleura.
Schrump DS; Fischette MR; Nguyen DM; Zhao M; Li X; Kunst TF; Hancox A; Hong JA; Chen GA; Pishchik V; Figg WD; Murgo AJ; Steinberg SM
Clin Cancer Res; 2006 Oct; 12(19):5777-85. PubMed ID: 17020984
[TBL] [Abstract][Full Text] [Related]
8. Depsipeptide induces cell death in Hodgkin lymphoma-derived cell lines.
Hartlapp I; Pallasch C; Weibert G; Kemkers A; Hummel M; Re D
Leuk Res; 2009 Jul; 33(7):929-36. PubMed ID: 19233470
[TBL] [Abstract][Full Text] [Related]
9. Tolerability, pharmacodynamics, and pharmacokinetics studies of depsipeptide (romidepsin) in patients with acute myelogenous leukemia or advanced myelodysplastic syndromes.
Klimek VM; Fircanis S; Maslak P; Guernah I; Baum M; Wu N; Panageas K; Wright JJ; Pandolfi PP; Nimer SD
Clin Cancer Res; 2008 Feb; 14(3):826-32. PubMed ID: 18245545
[TBL] [Abstract][Full Text] [Related]
10. Phase I trial of histone deacetylase inhibition by valproic acid followed by the topoisomerase II inhibitor epirubicin in advanced solid tumors: a clinical and translational study.
Münster P; Marchion D; Bicaku E; Schmitt M; Lee JH; DeConti R; Simon G; Fishman M; Minton S; Garrett C; Chiappori A; Lush R; Sullivan D; Daud A
J Clin Oncol; 2007 May; 25(15):1979-85. PubMed ID: 17513804
[TBL] [Abstract][Full Text] [Related]
11. Enhanced transgene expression in urothelial cancer gene therapy with histone deacetylase inhibitor.
Okegawa T; Nutahara K; Pong RC; Higashihara E; Hsieh JT
J Urol; 2005 Aug; 174(2):747-52. PubMed ID: 16006969
[TBL] [Abstract][Full Text] [Related]
12. A phase II study of depsipeptide in refractory metastatic renal cell cancer.
Stadler WM; Margolin K; Ferber S; McCulloch W; Thompson JA
Clin Genitourin Cancer; 2006 Jun; 5(1):57-60. PubMed ID: 16859580
[TBL] [Abstract][Full Text] [Related]
13. Systemic co-administration of depsipeptide selectively targets transfection enhancement to specific tissues and cell types.
Liu Y; Liggitt D; Fong S; Debs RJ
Gene Ther; 2006 Dec; 13(24):1724-30. PubMed ID: 16886001
[TBL] [Abstract][Full Text] [Related]
14. Phase II study of weekly plitidepsin as second-line therapy for small cell lung cancer.
Eisen T; Thatcher N; Leyvraz S; Miller WH; Couture F; Lorigan P; Lüthi F; Small D; Tanovic A; O'Brien M
Lung Cancer; 2009 Apr; 64(1):60-5. PubMed ID: 18692272
[TBL] [Abstract][Full Text] [Related]
15. Gene expression profiling induced by histone deacetylase inhibitor, FK228, in human esophageal squamous cancer cells.
Hoshino I; Matsubara H; Akutsu Y; Nishimori T; Yoneyama Y; Murakami K; Komatsu A; Sakata H; Matsushita K; Ochiai T
Oncol Rep; 2007 Sep; 18(3):585-92. PubMed ID: 17671705
[TBL] [Abstract][Full Text] [Related]
16. Phase II, multicenter, uncontrolled trial of single-agent sorafenib in patients with relapsed or refractory, advanced non-small-cell lung cancer.
Blumenschein GR; Gatzemeier U; Fossella F; Stewart DJ; Cupit L; Cihon F; O'Leary J; Reck M
J Clin Oncol; 2009 Sep; 27(26):4274-80. PubMed ID: 19652055
[TBL] [Abstract][Full Text] [Related]
17. A proof-of-principle clinical trial of bexarotene in patients with non-small cell lung cancer.
Dragnev KH; Petty WJ; Shah SJ; Lewis LD; Black CC; Memoli V; Nugent WC; Hermann T; Negro-Vilar A; Rigas JR; Dmitrovsky E
Clin Cancer Res; 2007 Mar; 13(6):1794-800. PubMed ID: 17363535
[TBL] [Abstract][Full Text] [Related]
18. A histone deacetylase inhibitor enhances adenoviral infection of renal cancer cells.
Okegawa T; Sayne JR; Nutahara K; Pong RC; Saboorian H; Kabbani W; Higashihara E; Hsieh JT
J Urol; 2007 Mar; 177(3):1148-56. PubMed ID: 17296436
[TBL] [Abstract][Full Text] [Related]
19. Phase I/II study of atrasentan, an endothelin A receptor antagonist, in combination with paclitaxel and carboplatin as first-line therapy in advanced non-small cell lung cancer.
Chiappori AA; Haura E; Rodriguez FA; Boulware D; Kapoor R; Neuger AM; Lush R; Padilla B; Burton M; Williams C; Simon G; Antonia S; Sullivan DM; Bepler G
Clin Cancer Res; 2008 Mar; 14(5):1464-9. PubMed ID: 18316570
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of axitinib in patients with advanced non-small-cell lung cancer: results from a phase II study.
Schiller JH; Larson T; Ou SH; Limentani S; Sandler A; Vokes E; Kim S; Liau K; Bycott P; Olszanski AJ; von Pawel J
J Clin Oncol; 2009 Aug; 27(23):3836-41. PubMed ID: 19597027
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]